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A B S T R A C T
Purpose
The purpose of this analysis was to investigate trastuzumab-associated cardiac adverse
effects in breast cancer patients after completion of (neo)adjuvant chemotherapy with or
without radiotherapy.
Patients and Methods
The Herceptin Adjuvant (HERA) trial is a three-group, multicenter, open-label randomized trial that
compared 1 or 2 years of trastuzumab given once every 3 weeks with observation in patients with
HER-2–positive breast cancer. Only patients who after completion of (neo)adjuvant chemotherapy
with or without radiotherapy had normal left ventricular ejection fraction (LVEF  55%) were
eligible. A repeat LVEF assessment was performed in case of cardiac dysfunction.
Results
Data were available for 1,693 patients randomly assigned to 1 year trastuzumab and 1,693 patients
randomly assigned to observation. The incidence of trastuzumab discontinuation due to cardiac
disorders was low (4.3%). The incidence of cardiac end points was higher in the trastuzumab
group compared with observation (severe congestive heart failure [CHF], 0.60% v 0.00%;
symptomatic CHF, 2.15% v 0.12%; confirmed significant LVEF drops, 3.04% v 0.53%). Most
patients with cardiac dysfunction recovered in fewer than 6 months. Patients with trastuzumab-
associated cardiac dysfunction were treated with higher cumulative doses of doxorubicin (287
mg/m2 v 257 mg/m2) or epirubicin (480 mg/m2 v 422 mg/m2) and had a lower screening LVEF and
a higher body mass index.
Conclusion
Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and
the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be
considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.
J Clin Oncol 25:3859-3865. © 2007 by American Society of Clinical Oncology
INTRODUCTION
The human epidermal growth factor receptor 2
(HER-2/erbB2) is expressed in the adult myo-
cardium and plays an important role in the
modulation of anthracycline-associated cardio-
toxicity.1-3 Trastuzumab benefits patients with
metastatic breast cancer and improves disease-
free and overall survival after adjuvant chemo-
therapy.4-6 However, trastuzumab treatment
is also associated with congestive heart failure
and cardiac dysfunction.7-9 In the Herceptin
Adjuvant (HERA) trial, we therefore prospec-
tively monitored cardiac function in all patients
and report herein the cardiac safety data from
this trial.
PATIENTS AND METHODS
Study Design
The HERA trial was a three-group, multicenter,
open-label, phase III randomized trial involving women
with HER-2–positive early-stage invasive breast cancer
who completed locoregional therapy and a minimum of
four cycles of a standard (neo)adjuvant chemotherapeutic
regimen plus radiotherapy if indicated. The patients were
randomly assigned to the following three groups: women
who had observation only; those adjuvantly treated with
trastuzumab (first dose 8mgper kilogramof bodyweight,
then6mgperkilogramevery3weeks) for1year; and those
treatedwith trastuzumabat the samedoseandonthe same
schedule for 2 years.
The primary end point was disease-free survival and
secondary end points included cardiac safety, overall sur-
vival, time to recurrence, and time to distant recurrence.
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An interim efficacy analysis after 475 disease-free survival events showed a
highly significant improvement of disease-free survival for patients who were
randomly assigned to both 1 and 2 years of trastuzumab compared with the
observation group. The independent data monitoring committee recom-
mended release of the 1-year trastuzumab versus observation results. The
detailed efficacy results for 1-year trastuzumab versus observation with a
median follow-upperiodof 1 yearwere published.4All patients adhered to the
same schedule of follow-up visits.
To ensure comparability in both groups, patients in whom trastuzumab
treatment was stopped prematurely were asked to attend all planned remain-
ing study visits, if possible.
Eligibility Criteria
Patients with completely excised HER-2–positive early invasive breast
cancer were eligible for the study if they had completed at least four cycles of a
standard (neo) adjuvant chemotherapy regimen and radiotherapy (if applica-
ble). Chemotherapy could have included regimens with anthracyclines with
or without taxanes or nonanthracycline regimens. Anthracycline-containing
chemotherapy was not allowed to exceed a cumulative dose of 360 mg/m2
doxorubicin or 720 mg/m2 epirubicin. Irradiation of the mediastinal internal
mammary node had to be planned using three-dimensional computerized axial
tomography scanning or a similar technique tominimize cardiac irradiation.
Cardiac Eligibility Criteria
Onlypatientswhohada screeningLVEFafter completionof chemo-and
radiation therapy with a normal left ventricular ejection fraction (LVEF
 55% measured by echocardiography or multiple-gated acquisition
[MUGA] scan) were enrolled. Patients with a history of documented conges-
tive heart failure (CHF), coronary artery disease (angina pectoris requiring
antianginal medication or transmural infarction on ECG), uncontrolled hy-
pertension (blood pressure systolic 180mmHg or diastolic 100mmHg),
high-risk arrhythmias or clinically significant valvular disease were excluded.
Cardiac Monitoring
A cardiac questionnaire, physical examination, ECG, and an assessment
of LVEFby echocardiography orMUGAscanningwere performed in all three
study groups at baseline, 3, 6, 12, 18, 24, 30, 36, and 60 months after random
assignment. Among the first 900 patients enrolled, echocardiograms up to 6
months (the first three LVEF assessments) were reviewed by a core laboratory
blinded to the treatment group as a quality control measure and feedback to
the study site was given when necessary. The results of the review of echocar-
diograms by the core laboratory were presented to the independent data
monitoring committee. Three prespecified interim cardiac safety analyses
were performed after 300, 600, and 900 patients were treated or observed
for 6 months.
Definitions
Cardiac safety and tolerability of trastuzumabwere assessed on the basis
of prespecified cardiac end points. Cardiac death was defined as death defi-
nitely due to heart failure, myocardial infarction or documented arrhythmia,
or probable cardiac death within 24 hours of a cardiac event. A significant
LVEF drop was defined as an absolute decline of at least 10 percentage points
from baseline LVEF and to below 50% identified byMUGA scan or echocar-
diogram. Severe CHF was defined as New York Heart Association (NYHA)
class III or IV, confirmed by a cardiologist, and a significant LVEF drop.
Symptomatic CHFwas defined as symptomatic CHF confirmed by a cardiol-
ogist and a significant LVEF drop. Confirmed significant LVEF drop was
defined as an asymptomatic (NYHA class I) or mildly symptomatic (NYHA
class II) significantLVEFdrop,unless thenext subsequent assessmentofLVEF
indicated a return to levels that did not meet the definition of a significant
LVEF drop; or as identified by the treatment unblinded cardiac advisory
board. A repeat LVEF assessmentwas to be performed approximately 3weeks
after the first documented significant LVEF drop andNYHA class II was to be
confirmed by a cardiologist. If such a repeat assessment or confirmation of
NYHAclass was not available, the cardiac advisory board reviewed the patient
and adjudicated the cardiac end point. The primary cardiac end point of this
studywas cardiac deathor severeCHF.The secondary cardiac endpoint of the
study was a confirmed significant LVEF drop.
Discontinuation of Trastuzumab and Dose Modification
Trastuzumabhad tobepermanently discontinued inpatientswho expe-
rienced severe CHF (a primary cardiac end point) and heart failure treatment
was recommended. Forpatientswith a significantLVEFdrop, continuationor
discontinuation with trastuzumab was guided by the algorithm depicted in
Appendix Figure A1 (online only). If the patient reached a confirmed signifi-
cant LVEF drop (a secondary cardiac end point) trastuzumab had to be
permanently discontinued. Reasons for premature discontinuation of trastu-
zumabduring the scheduled treatment period are presented inTable 1.A total
of 153 patients (9.1%) discontinued for reasons other than recurrence of
disease. Seventy-twopatients (4.3%)discontinued trastuzumabtreatmentdue
to cardiac disorders. The cardiac disorders leading to discontinuation were
CHF (n 30), left ventricular dysfunction (n 32), manifestation of coro-
nary artery disease (n 1), tachyarrthymias (n 2), pericardial effusion (n
1), new ECG abnormalities (n  2), and unspecific cardiotoxicity (n  4).
Forty patients (2.4%) refused trastuzumab treatment and 29 patients (1.7%)
discontinued due to other non-cardiac adverse events.
Statistical Analysis
The clinical cutoff date for this analysis was March 29, 2005. Data were
available for 3,386 patients randomly assigned between December 2001 and
March 2005: 1,693 were randomly assigned to observation and 1,693 patients
were randomly assigned to 1 year of trastuzumab.
The safety population groupswere definedbywhether a patient received
trastuzumab before disease recurrence. There were 19 patients randomly as-
signed to the 1-year trastuzumab group who did not receive any trastuzumab
before disease recurrence and four patients randomly assigned to observation
who received at least one dose of trastuzumab. Therefore, there were 1,678
patients in the trastuzumab safety analysis population group and 1,708 pa-
tients in the observation safety analysis population group.
The difference in incidence of cardiac adverse events between safety
analysispopulationgroupswas comparedwithanapproximate95%CI for the
difference of two incidences using the Hauck-Anderson correction.10 The
mean cumulative dose of chemotherapy agentswas compared amongpatients
with and without any cardiac end points in the trastuzumab safety analysis
populationgroupusinga t-test assumingequal variances.The incidenceof any
cardiac endpointwas estimated for the trastuzumabsafety analysispopulation
group according to potential cardiac risk factors.
RESULTS
Patient Characteristics
The demographic characteristics of patients in the two safety
analysis population groups with respect to age, race (white, 84% v
83%), menopausal status (postmenopausal, 45% in both groups),
smokinghabits (smoker, 14% v 13%), previous or active cardiovascu-
lardiseases (22%v23%),hypertension(17%inbothgroups),diabetes
(3% in both groups), and previous radiotherapy (received radio-
therapy, 77% v 76%) were balanced in both groups. The mean age
Table 1. Reason for Discontinuation of Trastuzumab
Reason for Discontinuation
Patients (N  1,678)
No. %
Cardiac disorders 72 4.3
Other non-cardiac adverse events 29 1.7
Death 3 0.2
Recurrence of disease 69 4.1
Refused treatment 40 2.4
Other reason 9 0.5
Total 222
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( standard deviation) of patients in the two groups was 49 10
years. Patients received a minimum of four cycles of adjuvant
(89%), neoadjuvant (5%), or both (6%) types of chemotherapy.
The (neo)adjuvant chemotherapy was anthracycline based in 94%
of patients, and in addition, 26% received taxanes. The median
time between finishing any type of chemotherapy and start of
trastuzumab treatment was 89 days.
Cardiac End Points
The incidence of CHF is shown in Table 2. One patient in the
observation group suffered cardiac death. As expected, the incidence
of severe CHF (0.60 v 0.00; 95%CI for difference in incidence, 0.20%
to 0.99%), symptomatic CHF (2.15 v 0.12; 95% CI for difference in
incidence, 1.29% to 2.77%) and confirmed significant LVEF drop
(3.04% v 0.53%; 95%CI for difference in incidence, 1.59% to 3.43%)
was significantly higher in the trastuzumab group compared with
observation. The incidence of anoccurrence at any timeof at least one
significant LVEFdropwas also significantly higher in the trastuzumab
group (7.03% v 2.05%; 95%CI for the difference in incidence, 3.56%
to 6.41%).
Recovery After a Cardiac End Point
Of the 10 patients in the trastuzumab group with severe CHF,
eight were asymptomatic at the last scheduled assessment onDecem-
ber 15, 2005 (Table 3). A patient’s LVEF was considered recovered
from a cardiac end point if the patient had an LVEF of 55% at any
timeafter the cardiac endpointuntilDecember15, 2005.Aspresented
in Table 3, six of 10 patients with severe CHF recovered their LVEF in
a median of 124 days (range, 36 to 409 days). Among the 36 patients
with symptomaticCHF, 24patients recovered their LVEF in amedian
of 151 days (range, 26 to 831 days) and among the 51 patients with a
confirmedsignificantLVEFdrop,35patients recovered inamedianof
191 days (range, 13 to 831 days).
Cumulative Dose of Chemotherapy Agents
The mean cumulative dose of chemotherapy agents cyclophos-
phamide, doxorubicin, epirubicin, docetaxel, and paclitaxel was cal-
culated for patients who had reached a cardiac end point and patients
whodidnot reacha cardiac endpoint (Table4).Themeancumulative
dose among patients with a cardiac end point was significantly higher
for doxorubicin (287 mg/m2 v 257 mg/m2) and epirubicin (480
mg/m2 v 422mg/m2). Therewere four patients treatedwith paclitaxel
who developed a cardiac end point. The mean cumulative dose of
Table 2. Cardiac Adverse Events (safety analysis population)
Variable
Trastuzumab
(n  1,678)
Observation
(n  1,708)
Difference in
Incidence
95% CI for
Difference in
IncidenceNo. % No. %
Cardiac death 0 0.00 1 0.06 0.06 0.20 to 0.09
Severe CHF (not including cardiac death) 10 0.60 0 0.00 0.60 0.20 to 0.99
Symptomatic CHF (including severe CHF, not
including cardiac death)†
36 2.15 2 0.12 2.03 1.29 to 2.77
Confirmed significant LVEF drop (asymptomatic
or mildly symptomatic)‡
51 3.04 9 0.53 2.51 1.59 to 3.43
Any type of cardiac end point (at least one occurrence of
cardiac adverse events above)§
61 3.64 10 0.59 3.05 2.05 to 4.05
At least one significant LVEF drop¶ 118 7.03 35 2.05 4.98 3.56 to 6.41
Abbreviations: CHF, congestive heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Severe CHF, which does not include death from cardiac causes, was defined as NYHA III or IV functional class confirmed by a cardiologist and a decrease in LVEF
of  10 percentage points below baseline and to less than 50%.
†Symptomatic CHF, which includes severe CHF, was defined as CHF that was considered symptomatic by a cardiologist and a decrease in LVEF of  10
percentage points below baseline and to less than 50%.
‡Confirmed asymptomatic (NYHA class I) or mildly symptomatic (NYHA class II) LVEF drop to  10 percentage points below baseline and to less than 50%, which
was confirmed after approximately 3 weeks. If such a repeat assessment was not available, the Cardiac Advisory Board reviewed the patient and determined if the
patient experienced a confirmed significant LVEF drop. This does not include patients with severe CHF.
§Any type of cardiac endpoint was defined as at least one occurrence of cardiac death, severe CHF, symptomatic CHF or confirmed significant LVEF drop.
¶Significant LVEF drop was defined as a decrease in LVEF of  10 percentage points below baseline and to less than 50% at any time during the study.
Table 3. Recovery After a Cardiac Event (trastuzumab safety
analysis population)
Event No. %
Time to
Recovery (days)
Median Range
Severe CHF† (n  10)
Recovery to asymptomatic 8 80
Recovery of LVEF  55% 6 60 124 36-409
Symptomatic CHF‡ (n  36)
Recovery of LVEF  55% 24 67 151 26-831
Confirmed significant LVEF drop§ (n  51)
Recovery of LVEF  55% 35 69 191 13-831
Any type of cardiac end point (n  61)
Recovery of LVEF  55% 41 67 189 13-831
Abbreviations: CHF, congestive heart failure; LVEF, left ventricular ejection
fraction; NYHA, New York Heart Association.
Treatment included angiotensin converting enzyme inhibitors (67%),
digoxin (44%), and beta blocker (33%).
†Severe CHF, which does not include death from cardiac causes, was
defined as NYHA III or IV functional class confirmed by a cardiologist and
a decrease in LVEF of  10 percentage points below baseline and to less
than 50%.
‡Symptomatic CHF, which includes severe CHF, was defined as CHF that
was considered symptomatic by a cardiologist and a decrease in LVEF of 10
percentage points below baseline and to less than 50%.
§Confirmed asymptomatic (NYHA class I) or mildly symptomatic (NYHA class
II) LVEF drop to  10 percentage points below baseline and to less than 50%,
which was confirmed after approximately 3 weeks. If such a repeat assess-
ment was not available, the cardiac advisory board reviewed the patient and
determined if the patient experienced a confirmed significant LVEF drop. This
does not include patients with severe CHF.
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paclitaxel showed a trend to a higher dose among patients with
a cardiac end point that was not significant and was based on
small numbers.
Potential Cardiac Risk Factors
Several potential cardiac risk factors were analyzed, as presented
in Table 5. The potential risk factors that were considered at baseline
were screening LVEF, history of cardiac disease, CHF, coronary
artery disease, previous radiotherapy, hypertension, high body
mass index, low bodymass index, current smoker, hyperlipidemia,
diabetes mellitus, hyperthyroidism, hypothyroidism, and age. The
incidence of any type of cardiac end point among patients with the
risk factor was compared with the incidence of any type of cardiac
end point among patients without the risk factor for the trastu-
zumab group. Patients with a screening LVEF of 55%  LVEF
 60% had a significantly higher incidence of cardiac end points
than patients with a higher screening LVEF  60% (6.90% v
2.72%; 95% CI for the difference in incidence, 1.33% to 7.02%).
Patients with a screening LVEF of 60%  LVEF  65% had
significantly higher incidence of cardiac end points than patients
with a higher screening LVEF 65% (3.89% v 1.88%; 95% CI for
the difference in incidence, 0.02% to 4.01%). It is to be expected
that patients with a lower screening LVEF have a higher inci-
dence of cardiac end points. Patients with a high body mass
index ( 25) had a significantly higher incidence of cardiac end
points than patients with a body mass index in the normal range
(20  BMI  25). Patients with a risk factor of hypertension,
current smoker, diabetes, hypothyroidism, or age 60 showed
a trend to a higher incidence of cardiac end points that was not
significant. There are small numbers of patients ( 60) with the
following risk factors: CHF, coronary artery disease, and diabetes
mellitus, leading towideCIs. Itwas not possible to considermetabolic
syndrome as a potential risk factor as only one patient had been
diagnosed with this condition.
Cumulative Incidence
The cumulative incidence for cardiac death or severe CHF
(Fig 1A), cardiac death, severe CHF or symptomatic CHF (Fig 1B),
and any cardiac endpoint (Fig 1C)were calculated and are displayed
alongwith the competing risk of a disease-free survival event.11 The
median follow-up for patients was 12 months.
DISCUSSION
HER signaling plays an important role in modulating myocardial
response to chemotherapy-induced injury and inhibitionof theHER-
2/erbB2 receptor worsens anthracycline-associated cardiotoxicity.1,12
Early clinical experience with trastuzumab in the pivotal trials indi-
cated a high potential for cardiotoxicity.6 To ensure safety for patients
in theHERA trial, we therefore applied an algorithm for discontinua-
tion of trastuzumab in individual patients based on periodic LVEF
assessment and we carefully monitored cardiac symptoms and func-
tion in all patients.
Cardiac events were infrequent in the HERA trial. No cardiac
deaths occurred in the trastuzumab group and the rate of severe heart
failure was 1%. Trastuzumab treatment was discontinued because
of cardiac dysfunction for 4.3% of patients.
The comparison with other trials is complicated by the fact that
differentdefinitionsof cardiac endpoints, eligibility criteria, and treat-
ment regimens were used. For example, the investigators of the Na-
tional Surgical Adjuvant Breast andBowel Project (NSABP)B-31 trial
defined a cardiac event as a probable/definite cardiac death or NYHA
III/IVCHF, confirmedby the cardiac reviewpanel,whichwasblinded
to treatment.9 In theHERA trial, tomeet thedefinitionof severeCHF,
NYHA III/IV CHF was confirmed by a local, unblinded cardiologist
and a significant LVEFdropwas required.The eligibility criteria of the
NSABP B-31 trial stated that a patient must not begin treatment with
trastuzumab if the patient’s LVEF was below the institution’s lower
limit of normal (which ismost often an LVEF 49%) or the patient’s
LVEF after anthracyclines or cyclophosphamide was at least 15%
below baseline. Furthermore, the treatment regimen in the NSABP
B-31 trial combined paclitaxel with weekly trastuzumab in the first 4
weeks after four cycles of anthracyclines or cyclophosphamide
whereas in the HERA trial once every 3weeks trastuzumab was given
after a median time of 89 days after completion of chemotherapy.
However, despite these complications, comparing the incidence of
severe CHF in the treatment groups, the incidence in the HERA trial
(0.6%) appears noticeably lower than in theNSABPB-31 (3.6%). The
percent of patients who prematurely discontinued trastuzumab be-
causeof cardiacdysfunctionwas4.3%inHERAcomparedwith15.6%
(133 of 850) in NSABP B-31.
It may also be possible to compare the incidence of left ventricu-
lar (LV) dysfunction in the two trials. The NSABP B-31 reports the
cumulative incidence of asymptomatic cardiac dysfunction, defined
as at least once adrop inLVEF10percentage points and to less than
Table 4. Mean Cumulative Dose of Chemotherapy Agents by Cardiac End Point Status (trastuzumab safety analysis population)
Agent
Cardiac End Point (n  61)
No Cardiac End Point
(n  1,617)
95% CI for
Difference in Means P
Mean Cumulative
Dose (mg/m2) SD
Mean Cumulative
Dose (mg/m2) SD
Cyclophosphamide (n  1,606) 3,442 1,146 3,253 1,293 161 to 538 .29
Doxorubicin (n  577) 287 58 257 54 5 to 55 .02
Epirubicin (n  1,018) 480 119 422 105 25 to 92  .01
Docetaxel (n  187) 386 76 375 105 69 to 89 .80
Paclitaxel (n  267) 838 170 642 223 25 to 415 .08
Abbreviation: SD, standard deviation.
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55%, of 34% in the treatment group, and of 17% in the observation
group. We report the incidence of at least one significant LVEF drop
( 10 percentage points below baseline and  50%), which may
include symptomatic patients, of 7.0% in the treatment group, and
of 2.1% in the observation group. Although not a formal
comparison, this suggests that trastuzumab-treatment regimen
in the HERA trial leads to a smaller increase in LV dysfunction.
Administering trastuzumab after completing chemotherapy
and radiotherapy, and restricting enrollment to patients with
LVEF 55% after chemotherapy, might contribute to the lower
incidence of LV dysfunction.
An important feature of trastuzumab-associated cardiotoxicity
might be reversibility of symptoms and LV dysfunction.13,14 As of the
last scheduled visit inDecember 15, 2005, 80%of patients with severe
CHF were asymptomatic. Sixty percent had a recovery of their LV
dysfunction to at least 55%as ofDecember 15, 2005. For patientswith
Table 5. Summary of Incidence of Cardiac End Point by Risk Factors (trastuzumab safety analysis population)
Variable
No. of
Patients
Incidence
95% CI for
Incidence
Difference in
Incidence
(%)
95% CI for the
Difference†No %
Screening LVEF
55%  LVEF  60% v 377 26 6.90 4.55 to 9.94 4.17 1.33 to 7.02
 60% 1,286 35 2.72 1.90 to 3.76
60%  LVEF  65% v 540 21 3.89 2.42 to 5.88 2.01 0.02 to 4.01
 65% 746 14 1.88 1.03 to 3.13
Cardiac history
Yes 374 16 4.28 2.46 to 6.85 0.83 1.59 to 3.24
No 1,304 45 3.45 2.53 to 4.59
Congestive heart failure
Yes 4 0 0.00 0.00 to 60.24 3.64 17.04 to 9.75
No 1,674 61 3.64 2.80 to 4.66
Coronary artery disease
Yes 16 0 0.00 0.00 to 20.59 3.67 7.70 to 0.36
No 1,662 61 3.67 2.82 to 4.69
Previous radiotherapy
Left sided 654 24 3.67 2.37 to 5.41 0.60 3.24 to 2.04
None 375 16 4.27 2.46 to 6.84
Hypertension
Yes 290 13 4.48 2.41 to 7.54 1.02 1.72 to 3.77
No 1,388 48 3.46 2.56 to 4.56
High BMI
 25 v 841 40 4.76 3.42 to 6.42 2.64 0.78 to 4.50
20  BMI  25 708 15 2.12 1.19 to 3.47
Low BMI
 20 118 6 5.08 1.89 to 10.74 2.97 1.58 to 7.51
20  BMI  25 708 15 2.12 1.19 to 3.47
Smoker
Yes 239 12 5.02 2.62 to 8.61 1.62 1.52 to 4.75
No 1,439 49 3.41 2.53 to 4.48
Hyperlipidaemia
Yes 74 1 1.35 0.03 to 7.30 2.39 5.87 to 1.09
No 1,604 60 3.74 2.87 to 4.79
Diabetes
Yes 56 5 8.93 2.96 to 19.62 5.48 3.01 to 13.96
No 1,622 56 3.45 2.62 to 4.46
Hyperthyroidism
Yes 17 0 0.00 0.00 to 19.51 3.67 7.52 to 0.17
No 1,661 61 3.67 2.82 to 4.69
Hypothyroidism
Yes 74 5 6.76 2.23 to 15.07 3.27 3.24 to 9.77
No 1,604 56 3.49 2.65 to 4.51
Age, years
 50 to  59 v 539 18 3.34 1.99 to 5.23 0.44 2.52 to 1.63
 50 872 33 3.78 2.62 to 5.27
 60 v 267 10 3.75 1.81 to 6.78 0.13 2.54 to 2.80
 60 1,411 51 3.61 2.70 to 4.73
Abbreviations: LVEF, left ventricular ejection fraction; BMI, body mass index.
Exact 95% CI for one sample binomial using Pearson-Clopper method.
†Approximate 95% CI for difference of two rates using Hauck-Anderson correction.
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severe CHF whose LV dysfunction recovered, the median time to
recovery was fewer than 6 months. A similar percentage of patients
with symptomatic CHF or confirmed significant LVEF drops had a
recovery of the LV function. It remains possible that with longer
follow-up time a higher incidence of LV dysfunction recovery would
be observed. Continued follow-up is required to determine long-time
cardiac prognosis in these patients.
In the HERA trial, the patients who had a cardiac end point
received a significantly higher dose of epirubicin and doxorubicin
than the patients without. As in other trials, we found that patients
with a lower screening LVEF had a significantly higher incidence of a
cardiac end point. However, unlike the investigators in the NSABP
B-31, we found no evidence of older patients being at greater risk for
trastuzumab-associated cardiac dysfunction.8 In contrast to the retro-
spective analysis of the pivotal trials in metastatic breast cancer, we
found no evidence that previous cardiac disease, hyperlipidemia, or
hypertensionwasa risk factor foracardiacendpoint.Of interest is that
patients with a high body mass index have a significantly higher
incidence of a cardiac end point. However, it is important to remem-
ber that analysis of potential risk factors are exploratory based on a
small number of cardiac end points.
The cumulative incidence functions shown in Figure 1 illustrate
that the benefit of trastuzumab in terms of reducing the risk of a
disease-free survival event is greater than the increased risk of cardiac
adverse effects even within the first year of follow-up. In addition, the
benefit appears to increase into the second year of follow-upwhile the
cumulative incidence of any type of cardiac end point appears stable
after completion of trastuzumab at 12months.
Limitations
Median follow-up was 12 months, and therefore, at the time
of analysis many patients were still receiving trastuzumab. We
acknowledge that we have a limited picture of the risks associated
with trastuzumab treatment. However, the incidence of cardiac
end points is low and as the cumulative incidence of cardiac end
points appears to be stable after 12months, we expect the incidence
of cardiac end points to remain low with further follow-up. The
low incidence of cardiac end points made the exploratory analysis
of risk factors more difficult.
In conclusion, given the clear benefit in disease-free sur-
vival of 1-year trastuzumab, the low incidence of cardiac end
points, and the suggestion that cardiac dysfunction may be
reversible, adjuvant trastuzumab should be considered a stan-
dard treatment option for patients who fulfill the HERA trial
eligibility criteria.
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